Libman-Sacks Endocarditis

Authored by | Last edited

This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

This page has been archived. It has not been updated since 15/10/2009. External links and references may no longer work.

Synonyms: verrucous endocarditis

In 1924 Libman and Sacks published an account of atypical, sterile, verrucous vegetations on the heart in systemic lupus erythematosus (SLE).[1] Clusters of verrucae, looking like mulberries, were described on the ventricular surface of the posterior leaflet of the mitral valve and found at postmortem. The leaflet and the chordae tendinae are often adherent to the endocardium of the ventricular wall.

The disease is often missed at echocardiography. The spectrum of the disease has changed since the original description, as steroids and other treatments have changed the course of the disease. Life expectancy, whilst limited, is much higher than it was. The left side of the heart is affected more often than the right but even the endocardium can be affected. Regurgitation is more frequent than stenosis.

Although the condition is classically associated with SLE, it can also occur in antiphospholipid syndrome (APS),[2] whether primary or secondary. High antibody titres are associated with high risk.[3]

Libman-Sacks' vegetations can be found in approximately 1 of 10 patients with SLE. They are associated with lupus duration, disease activity, anticardiolipin antibodies and APS manifestations.[4] The incidence of positive findings on echocardiography is variable but detection is higher with transoesophageal ultrasound and the frequency is higher in those with positive antiphospholipid antibodies.[5] Thickening of the leaflets is more common than finding vegetations. Abnormalities on ultrasound may be found in around a third with APS.

The presence of these findings, as with the disease, is 5 to 9 times more frequent in women than in men. The typical patient is a young woman, although it can rarely occur in children.

  • Most patients with Libman-Sacks endocarditis are asymptomatic.
  • If valves are severely affected there may be features of the valve disease. Mitral valve disease is more common than aortic valve disease. Regurgitation is more frequent than stenosis and involvement of the tricuspid or pulmonary valves is unusual.
  • Systemic embolism may occur with effects depending upon the destination of the emboli but brain and kidney are likely victims. Emboli can cause blockage of the peripheral circulation.
  • The vegetations of Libman-Sacks endocarditis are sterile but secondary infective endocarditis can occur.
  • There may or may not be typical features of SLE with the characteristic butterfly rash, fever and arthritis or features of APS, including recurrent miscarriage.
  • Physical signs reflect the pathology and can be found in the various articles on mitral valve disease or aortic valve disease, infective endocarditis and, if the valve disease is severe, congestive heart failure.
  • There may also be left ventricular hypertrophy, causing displacement of the apex beat.
  • Echocardiography should be employed, although not all lesions will be detected. Results with transoesophageal echo are superior but it is an invasive procedure.
  • Blood culture is important to exclude infective endocarditis (IE), which may coexist.
  • Investigations for SLE, including antiphospholipid antibodies and other autoantibodies. False positive serology in the form of VDRL is common in SLE and anticardiolipin antibodies increase the risk of cardiac abnormalities.[6]
  • FBC may show raised neutrophils and some anaemia.
  • CXR may show cardiomegaly and pulmonary congestion if disease is severe. Calcification of lesions is uncommon.
  • If valvular disease seems severe then cardiac catheterisation may be required with a view to valve replacement.
  • There is no specific treatment for Libman-Sacks endocarditis.
  • Steroids and immunosuppressive agents are useful in the treatment of the underlying disease but there is some controversy about their role in the pathogenesis of vegetations:
    • Compared with reports of postmortems on patients before the advent of steroids, those that have been treated have smaller and fewer lesion, mostly on one valve and usually confined to the left side.
    • Hypertension was 5 times as common and congestive heart failure was 8 times as common as in the days before corticosteroids.[7] The steroids may be directly responsible for the hypertension and heart failure. This paper was from 1975 and it is possible that better control of hypertension and heart failure may offset these problems today.
    • Expert opinion seems to conclude that steroids are detrimental to Libman-Sacks endocarditis[8] although some praise them.[9] The situation is far from certain.[10]
  • Advice for procedures creating risk of infective endocarditis can be found in the separate record Prevention of Endocarditis.
  • If there are systemic emboli then anticoagulation is beneficial but the possible role of aspirin has not been adequately investigated.[8] If there is evidence of 1 cerebrovascular event, anticoagulation is advised.[11]
  • In serious valve disease it may be necessary to replace valves. Mechanical valves may be more susceptible to thromboemboli but it is uncertain if bioprosthetic valves are at risk of the disease. The operative mortality of mitral valve replacement in this condition may be as high as 25%.[12]
  • Systemic emboli may occur but they are probably not very common.
  • The risk is much higher with mitral stenosis and subsequent atrial fibrillation.
  • When strokes occur it is difficult to know if they were due to systemic emboli or the underlying pathology of SLE or APS.
  • Valvular disease can lead to heart failure.
  • Maternal SLE with anti-Ro/SS-A (Sjögren's syndrome antigen A) autoantibodies is associated with congenital heart block in the baby in about 1 or 2%. It is usually complete but can be 1st or 2nd degree. The rate of recurrence is around 16%. Fluorinated steroids that do not cross the placenta may be beneficial.[13]

All patients with SLE have a shorter life span; cardiovascular disease is a common cause of death.

  • Emanuel Libman[14] and Benjamin Sacks[15] (or Sachs) described an unusual type of endocarditis in 1924, non-bacterial, with verrucous vegetations adherent to the endocardium. Dermatologists had earlier described the disease associated with facial rash and fever, but Libman and Sacks presented the first complete clinical picture, with and without skin lesions.
  • Libman was at the time assistant pathologist at Mount Sinai hospital in New York. He was an eccentric generalist, who founded the cardiology department, and made important contributions in bacteriology and teaching. He diagnosed the fatal endocarditis of Gustav Mahler, and said of Franklin D Roosevelt in 1944: "It doesn't matter whether Roosevelt is re-elected or not, he'll die of a cerebral haemorrhage within 6 months." After the event, he was asked how he knew: "I only saw him in the newsreels, but I've seen that special wasting look many times. He couldn't last 6 months."
  • APS (Hughes' syndrome, or as he first named it - anticardiolipin syndrome), was described by Graham Hughes in 1983, characterised by venous and/or arterial thrombosis, recurrent pregnancy loss, and the presence of antiphospholipid antibodies. Graham Hughes, rheumatologist at St Thomas' Hospital, was the first non-American to be elected to the American Lupus "Hall of Fame" in 1989, and set up the first dedicated Lupus outpatient facility outside the USA in 1997, the 'Louise Coote Lupus Unit' based within St Thomas' Hospital.
  • The association between Libman-Sacks endocarditis and APS was first noted in 1985.

Further reading and references

  • Ren X; Libman-Sachs Endocarditis emedicine. September 2008.

  1. Libman E, Sacks B: A hitherto undescribed form of valvular and mural endocarditis.; Arch Intern Med 1924 33: 701-37.

  2. Brenner B, Blumenfeld Z, Markiewicz W, et al; Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol. 1991 Oct18(4):931-6.

  3. Turiel M, Sarzi-Puttini P, Peretti R, et al; Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005 Aug 1596(4):574-9.

  4. Moyssakis I, Tektonidou MG, Vasilliou VA, et al; Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007 Jul120(7):636-42.

  5. Khamashta MA, Cervera R, Asherson RA, et al; Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 1990 Jun 30335(8705):1541-4.

  6. Nihoyannopoulos P, Gomez PM, Joshi J, et al; Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation. 1990 Aug82(2):369-75.

  7. Bulkley BH, Roberts WC; The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975 Feb58(2):243-64.

  8. Hojnik M, George J, Ziporen L, et al; Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996 Apr 1593(8):1579-87.

  9. Nesher G, Ilany J, Rosenmann D, et al; Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum. 1997 Aug27(1):27-35.

  10. Fluture A, Chaudhari S, Frishman WH; Valvular heart disease and systemic lupus erythematosus: therapeutic implications. Heart Dis. 2003 Sep-Oct5(5):349-53.

  11. Aziz F, Baciewicz FA Jr; Lambl's excrescences: review and recommendations. Tex Heart Inst J. 200734(3):366-8.

  12. Dajee H, Hurley EJ, Szarnicki RJ; Cardiac valve replacement in systemic lupus erythematosus. A review. J Thorac Cardiovasc Surg. 1983 May85(5):718-26.

  13. Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, et al; Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus. 200514(9):660-4.

  14.; Emanuel Libman Brief biography

  15.; Benjamin Sacks Brief biography